HK1124767A1 - Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor - Google Patents
Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptorInfo
- Publication number
- HK1124767A1 HK1124767A1 HK09102248.7A HK09102248A HK1124767A1 HK 1124767 A1 HK1124767 A1 HK 1124767A1 HK 09102248 A HK09102248 A HK 09102248A HK 1124767 A1 HK1124767 A1 HK 1124767A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benzoimidazol
- pyridines
- receptor
- histamine
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78818806P | 2006-03-31 | 2006-03-31 | |
PCT/US2007/008217 WO2007117400A2 (en) | 2006-03-31 | 2007-03-30 | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1124767A1 true HK1124767A1 (en) | 2009-07-24 |
Family
ID=38581555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09102248.7A HK1124767A1 (en) | 2006-03-31 | 2009-03-09 | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor |
Country Status (10)
Country | Link |
---|---|
US (1) | US7589087B2 (es) |
EP (1) | EP2004188B1 (es) |
JP (1) | JP2009532367A (es) |
CN (1) | CN101460168B (es) |
AT (1) | ATE479678T1 (es) |
AU (1) | AU2007235577B2 (es) |
DE (1) | DE602007008859D1 (es) |
ES (1) | ES2349237T3 (es) |
HK (1) | HK1124767A1 (es) |
WO (1) | WO2007117400A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5301999B2 (ja) † | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Cetp阻害薬 |
JP2009532367A (ja) | 2006-03-31 | 2009-09-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンh4受容体のモジュレーターとしてのベンゾイミダゾール−2−イルピリジン |
PT2007752E (pt) * | 2006-03-31 | 2010-10-18 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4 |
US20090069343A1 (en) * | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
ATE549351T1 (de) | 2007-01-30 | 2012-03-15 | Janssen Pharmaceutica Nv | Chimärer peptidantagonist für gpcr135 oder gpcr142 |
US8084466B2 (en) * | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
CA2727627C (en) * | 2008-06-12 | 2018-02-13 | Janssen Pharmaceutica Nv | Use of histamine h4 antagonist for the treatment of post-operative adhesions |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
UA102855C2 (ru) * | 2008-06-30 | 2013-08-27 | Янссен Фармацевтика Нв | Способ получения бензоимидазол-2-илпиримидиновых производных |
AU2013204436B2 (en) * | 2008-06-30 | 2014-12-04 | Janssen Pharmaceutica Nv | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
UA106724C2 (uk) * | 2008-06-30 | 2014-10-10 | Янссен Фармацевтика Нв | Спосіб отримання заміщених піримідинових похідних |
JP5721631B2 (ja) * | 2008-11-06 | 2015-05-20 | ムスク ファウンデーション フォー リサーチ デベロップメント | 酸性セラミダーゼのリソソーム親和性阻害剤 |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
MY180726A (en) | 2013-03-06 | 2020-12-08 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1007026A4 (en) | 1997-01-17 | 2002-08-07 | Merck & Co Inc | INTEGRIN ANTAGONISTS |
AU9663798A (en) | 1997-10-06 | 1999-04-27 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
US6489344B1 (en) | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
ME00370B (me) | 1999-06-23 | 2011-05-10 | Sanofi Aventis Deutschland | SUPSTITUISANI BENZIMIDAZOLl |
TR200103147T1 (tr) | 1999-12-27 | 2002-06-21 | Japan Tobacco Inc. | Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı. |
WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
EP1370250A2 (en) | 2001-03-23 | 2003-12-17 | Chugai Seiyaku Kabushiki Kaisha | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
US7314937B2 (en) * | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
DE60326735D1 (de) | 2002-08-02 | 2009-04-30 | Genesoft Pharmaceuticals Inc | Biaryl-verbindungen mit antiinfektiver wirkung |
CA2497829A1 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Method to treat allergic rhinitis |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
CA2528805A1 (en) | 2003-08-13 | 2005-05-06 | Chiron Corporation | Gsk-3 inhibitors and uses thereof |
US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
CN1886380B (zh) | 2003-09-30 | 2010-12-22 | 詹森药业有限公司 | 苯并咪唑化合物 |
EP1670739A4 (en) | 2003-10-08 | 2007-08-08 | Bristol Myers Squibb Co | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS |
BR0318576A (pt) * | 2003-11-11 | 2006-10-10 | Wockhardt Ltd | processo para a fabricação de 1,2-benzisoxazol-3-metanossulfonamida |
JP5162236B2 (ja) | 2004-03-25 | 2013-03-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | イミダゾール化合物 |
EP1824832B1 (en) | 2004-06-30 | 2011-04-27 | Janssen Pharmaceutica NV | Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents |
WO2006042102A2 (en) * | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
CA2602583A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
JP5301999B2 (ja) | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Cetp阻害薬 |
JP2009532367A (ja) | 2006-03-31 | 2009-09-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンh4受容体のモジュレーターとしてのベンゾイミダゾール−2−イルピリジン |
PT2007752E (pt) | 2006-03-31 | 2010-10-18 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4 |
US20090069343A1 (en) | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
-
2007
- 2007-03-30 JP JP2009503075A patent/JP2009532367A/ja active Pending
- 2007-03-30 WO PCT/US2007/008217 patent/WO2007117400A2/en active Application Filing
- 2007-03-30 DE DE602007008859T patent/DE602007008859D1/de active Active
- 2007-03-30 EP EP07754701A patent/EP2004188B1/en active Active
- 2007-03-30 CN CN2007800202694A patent/CN101460168B/zh not_active Expired - Fee Related
- 2007-03-30 US US11/731,048 patent/US7589087B2/en active Active
- 2007-03-30 AU AU2007235577A patent/AU2007235577B2/en not_active Ceased
- 2007-03-30 AT AT07754701T patent/ATE479678T1/de not_active IP Right Cessation
- 2007-03-30 ES ES07754701T patent/ES2349237T3/es active Active
-
2009
- 2009-03-09 HK HK09102248.7A patent/HK1124767A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2004188A4 (en) | 2009-04-22 |
WO2007117400A3 (en) | 2008-02-21 |
EP2004188B1 (en) | 2010-09-01 |
US7589087B2 (en) | 2009-09-15 |
WO2007117400A2 (en) | 2007-10-18 |
ATE479678T1 (de) | 2010-09-15 |
JP2009532367A (ja) | 2009-09-10 |
EP2004188A2 (en) | 2008-12-24 |
CN101460168A (zh) | 2009-06-17 |
CN101460168B (zh) | 2013-07-17 |
DE602007008859D1 (de) | 2010-10-14 |
ES2349237T3 (es) | 2010-12-29 |
AU2007235577A1 (en) | 2007-10-18 |
AU2007235577B2 (en) | 2011-09-15 |
US20070232616A1 (en) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1124767A1 (en) | Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor | |
UA95949C2 (ru) | Бензоимидазол-2-илпиримидины и пиразины как модуляторы рецептора гистамина h4 | |
MY145349A (en) | Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor | |
MX2009008787A (es) | Moduladores 2-aminopirimidina del receptor de histamina h4. | |
MY158927A (en) | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor | |
WO2007117401A3 (en) | Indoles and benzoimidazoles as modulators of the histamine h4 receptor | |
MA32975B1 (fr) | Antagonistes de c5ar | |
WO2006074428A3 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
WO2007022506A3 (en) | Methods and compositions for treating neurological disease | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
IN2012DN02471A (es) | ||
CA2903737C (en) | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | |
MX2009008425A (es) | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. | |
MX2009001315A (es) | Compuestos de dimetilciclobutilo substituidos, su preparación y uso en medicamentos. | |
WO2011061744A3 (en) | Novel arylated camphenes, processes for their preparation and uses thereof | |
WO2010129048A3 (en) | Therapeutic compounds | |
WO2006135694A3 (en) | Uii-modulating compounds and their use | |
ATE475651T1 (de) | Aryl-substituierte heterozyklen und ihre verwendung | |
MX367916B (es) | Procedimientos para la preparacion de derivados de ciclopropilamida. | |
WO2007115192A3 (en) | P2x7 antagonists to treat affective disorders | |
JO2694B1 (en) | Pyramidines Benzo Imidazole-2-IL and Pyrazinate as histamine H4 receptor regulators | |
WO2010019565A3 (en) | Anti-ephrin b2 antibodies and their use in treatment of disease | |
UA106046C2 (uk) | Діамінопіридинові, піримідинові і піридазинові модулятори гістамінового рецептора h4 | |
MX2012003603A (es) | Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihid ropiridina fluoro-sustituidos y procedimientos de uso de los mismos. | |
WO2008057543A3 (en) | Uii-modulating compounds and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230330 |